As claimed by the heterogeneity (I2) results, random or fixed effects models were used to calculate the pooled incidence with its risk ratio (RR).<h4>Results</h4>A significantly elevated risk of high grade infection was associated with anti-EGFR therapy based on a meta-analysis of 10 randomized controlled trials (N = 7927). The gene discussed is EGFR; the disease is infection.